Abstract:

The incidence of malignant melanoma is low, the mortality is high, and the survival time is short. In the early stage, surgery is the main treatment; in the late stage, chemical drugs are mostly used, but the effective rate is not high. Immunotherapy has achieved advanced and breakthrough development in the treatment of a variety of malignant tumors, and has also been proved to prolong the survival time of malignant melanoma patients in clinical practice. This article is to share a case of metastatic malignant melanoma treated with toripalimab who has achieved good efficacy in the First Affiliated Hospital of Jinan University.

Key words:

Malignant melanoma, Toripalimab, Immunotherapy

摘要：

恶性黑色素瘤发病率低，致死率高、生存期短，早期以手术治疗为主，晚期多予以应用化学药物治疗，但有效率不高。免疫治疗在多种恶性肿瘤治疗中取得进阶性、突破性发展，同时也在临床中被证实可延长恶性黑色素瘤患者的生存时间。本文分享暨南大学附属第一医院1例特瑞普利单抗治疗转移性恶性黑色素瘤并获得较佳疗效的病例。

关键词:

恶性黑色素瘤, 特瑞普利单抗, 免疫治疗